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Summary
Aim: Developing extended release matrix tablets containing 350 mg ascorbic acid and hydrox-
ypropyl methylcellulose (HPMC) or polyethylene oxide (PEO) as hydrophilic polymer/s which
control the rate and degree of drug release through 12 hour period.
Materials and methods: Six batches of matrix tablets (P1, P2, P3, P4, P5, P6) were produced
by direct compression. Ascorbic acid 97% was used as active compound. HPMC K4M, HPMC
K15M, PEO 1105 and PEO 301 were used as hydrophilic polymers. Cellulose microcrystaline
was used as diluent, copovidone was employed as binder, colloidal silica as flow-aid while mag-
nesium stearate was used as lubricant. Before tableting powder mixtures were sieved and eval-
uated for bulk density, tapped density, angle of repose, compressibility index and Hausner ratio.
Compressed tablets were evaluated for average mass, hardness, friability, average drug content
and dissolution profile through 12 hours in phosphate buffer pH=7.2 . All test were conducted
according pharmacopoeial standards (PhEur 7 and USP 35)
Results: All six batches of powder mixtures demonstrated good flow properties and didn’t tend
to make any problems during tableting process. Also all six batches of tablets complied the
pharmacopeial requirements concerning average mass, hardness, friability and drug content.
Dissolution studies demonstrated that all six batches of tablets provided extended release of
ascorbic acid through 12 hours period, but only tablets containing PEO 1105, PEO 301 and
their 1:1 mixture liberated more than 80% active compound, which is generally due to the lower
viscosity and higher erodability of these PEO-s compared with the used HPMC-s. It was also
demonstrated that low viscosity PEO 1105 or HPMC K4M released higher percent of active
compound compared with higher viscosity PEO 301 or HPMC K15M, while both PEO
1105/PEO 301 1:1 mixture and HPMC K4M/HPMC K15M 1:1 mixture gave intermediate drug
release, which is connected to the intermediate viscosity obtained by mixing these polymers.
Conclusion: From the results received from all test it was concluded that tablets containing
PEO 1105 as hydrophilic polymer (P1) are the most suitable choice for developing 12 hour ex-
tended release matrix tablets containing 350mg ascorbic acid as active compound.
Key words: ascorbic acid, extended release tablets, polymer, hydroxypropyl methylcellulose,
polyethylene oxide
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Introduction
Ascorbic acid (Vitamin C) is a hydrosoluble
essential vitamin. Because of the incapability
to be produced by the body, humans must sup-
ply vitamin C via food (especially fruits and
vegetables) and/or via health supplements.
Ascorbic acid is best known by its antioxidant
activity, and the free radical scavenging
[Heber,2007]. Thereby it is very important for
tissue recovery, collagen synthesis, and many
oxidation-reduction reactions in the organism.
Ascorbic acid also takes part in the metabo-
lism of folic acid, tyrosine, phenylalanine,
iron, histamine etc. It supports the immune
system, it protects blood vessels, it increases
the absorption of iron in the GUT. Deficiency
of ascorbic acid in the human body may cause
scurvy, anemia, atherosclerotic plaques, bleed-
ing gums, muscle degeneration, neurotic dis-
turbances, poor wound healing [Iqbal et al,
2004]. The required daily dose of ascorbic
acid varies among the nutritional scientist
from several mg up to 1-2 g. The absorption
of the vitamin C from the GUT is up to70%
when smaller amounts are ingested (up to 180
mg). By increasing the dose the % of absorbed
vitamin C decreases down to 50% - 15%
[Iqbal et al,2004] Many countries have esti-
mated 60 mg ascorbic acid as RDA and 350
mg ascorbic acid as MDA for a dietary/health
supplement [Official gazzete of R.Macedo-
nia]. Developing extended release dosage
form of ascorbic acid will provide continuous
supply of small amounts of the active moiety
which could be easily absorbed from the
human GUT.
Extended release drug formulations became
very popular in the last two decades, since
they overcame some of the disadvantages of
conventional solid dosage forms (tablets and
capsules) such as fluctuations of the drug con-
centration in the plasma and on the site of ac-
tion, frequency of dosing, drug toxicity, costs
etc [Aulton, 2007].After administration ex-
tended release dosage forms provide continu-
ous supply of small but therapeutic amounts
of active compound at rates sufficiently con-
trolled to provide maintaining therapeutic
plasma concentration levels and prolonged
therapeutic action (usually between 8-12
hours). The main goal of formulators working
on extended release dosage forms in to
achieve linear zero order release of the active
moiety. There are several types of dosage
forms which provide extended release of the
active compound, and could be designed as
mono- or multi-dose units. Those are:




Hydrophilic matrix systems/tablets or also
called swellable-soluble systems are the most
investigated type of extended release dosage
forms. They consist of mixture of active com-
pound and a hydrophilic polymer, usually with
added suitable diluent/s, binders, lubricants
etc. These types of dosage forms may be pro-
duced by both direct compression or granula-
tion methods [Wen et al, 2010].Hydrophilic
matrix tablets, achieve extended release of an
active compound in presence of water by rapid
hydration and swelling of the polymer located
on the outer surface of the tablet and formation
of an outer porous gelatinous layer [Wen et al,
2010].This layer maintains tablet integrity and
prevents rapid disintegration. It also controls
the diffusion of the water medium inside the
matrix, and this is the reason why the outer gel
layer plays important role in controlling the
rate of drug release. Fast formation of an outer
gelatinous layer is crucial for obtaining suit-
able extended release matrix tablet.
Hydrophilic matrix tablets release the active
compound via two main mechanisms: diffu-
sion and erosion. By hydration and swelling
the polymer content on the outer surface of the
tablet forms a continuous porous gel layer
which enables water to penetrate inside the hy-
drated and swelled part of the matrix and to
dissolve the active compound. The dissolved
substance leaves the matrix by diffusion
through the gel layer. When the outer gel layer
fully hydrates it starts to erode and it is con-
tinuously replaced by new hydrated polymeric
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layer. By erosion of the matrix surface an
amount of active compound is released in the
outer media [Wen et al, 2010]. Therefore it
could be concluded that the release of the drug
from a hydrophilic matrix system depends
mainly on polymer features such as: molecular
weight, viscosity and swelling capacity, per-
meability and erosion of the outer gel layer but
also it is connected with properties such as:
drug solubility and matrix composition. [Salah
et al, 2010] The higher the molecular weight
and viscosity of the polymer are, longer time
period is required for complete drug release.
Usually hydrophilic matrix systems/tablets re-
lease the active compound by both diffusion
and erosion.
Hydroxypropyl methylcellulose (HPMC,
Hypromelose) or METHOCEL™ (marketed
by Dow and Colorcon) is most widely used
hydrophilic water soluble polymer for prepa-
ration of hydrophilic matrix systems/tablets. It
is compatible with many active compounds
and with most of the excipients used in mod-
ern solid dosage forms, it is pH independent,
it has good flowability and compressibility,
and gives tablets with reproducible character-
istics. HPMC appear in different molecular
weights and with different viscosity grades,
which makes it suitable for many pharmaceu-
tical purposes (modified release, tablet coat-
ing, tablet binding etc)[Rowe et al, 2006].
High viscosity grade HPMC-s (Methocel
K4M, Methocel K15M, Methocel K100M) are
mostly used as a modified release polymers.
They show quick hydration and formation of
a continuous gel layer which provide con-
trolled release of the active compound by both
diffusion and erosion while maintaining tablet
integrity during prolonged time periods [Tu et
al, 2010].An effort to formulate 100 mg
ciprofloxacine hydrochloride with HPMC
K100 LV , HPMC K4M ,HPMC K15M and
HPMC K100M was made by Rahman et al.
The dissolution studies through 8 hours period
showed that matrices containing HPMC K100
LV and HPMC K4M released more than 90 %
of the active compound in 6 hours while ma-
trices containing HPMC K15M and HPMC
K100M  provided extended release through 8
hours (around 90% drug released).[Rahman et
al, 2011]. These results demonstrated that drug
release from HPMC matrix tablets depends
mainly on polymer viscosity and molecular
weight.
Polyethylene oxide-s (PEO) are water soluble
resins commercially known as POLYOX™
(marketed by Dow and Colorcon) which in re-
cent years has attracted great attention as a
polymeric excipient that can be used in formu-
lation of pH independent hydrophilic matrices.
Due to their chemical structure, PEO-s are
among various hydrophilic polymers that, in
the presence of water, supply the active moiety
in controlled fashion by swelling and forming
a hydrogel, which lead to drug release by dif-
fusion and/or erosion [Pinto et al, 2004]. All
the attention paid to PEO-s is a consequence
of their physical and chemical stability, com-
pressibility, high swelling ability, and fast hy-
dration. Thus, PEO-s have been proposed as
alternatives to HPMC or other hydrophilic
polymers in the production of extended release
matrix tablets. PEO-s appear in different mo-
lecular weights and viscosity grades, from
which the ones with high molecular weights
and high viscosity values( POLYOX 1105,
POLYOX 301, POLYOX 303) are the most
suitable candidates for developing hydrophilic
matrix tablets [Rowe et al, 2006].. Maggi at al.
investigated the dissolution profile of dilti-
azeme hydrochloride from matrices containing
PEO 1105 and matrices containing PEO 301
made under stamp pressure of 10 kN and 30
kN [Maggi et al, 2002]. The obtained results
showed that lower viscosity polymer PEO
1105 released approximately 100% active
drug in period of 6 hours while matrices con-
taining higher viscosity PEO 301 released
around 75% of the incorporated diltiazem in
the same time interval. The tablet hardness
didn’t affect the release of the active moiety in
matrices containing the same polymer.
Mixing polymers from the same chemical en-
tity but with different physical properties in
different ratios provides modification of phys-
ical and chemical features of the matrix and
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often leads to modification of the rate and ex-
tent of drug release [Wen et al, 2010]. This
phenomenon is usually used for achieving spe-
cific release profile and site-specific activity
of some active compounds.Kumar et al. stud-
ied gastro-retentive hydrophilic matrices of
famotidine containing HPMC K4M and
HPMC K15M, and a mixture of these two
polymers in a 1:1 ratio [Kumar et al, 2009].
The obtained results showed that the formula-
tion containing polymer blend decreased the
% of drug released compared with formula-
tions containing single polymer.
The aim of this work was to formulate hy-
drophilic matrix tablets containing 350 mg
ascorbic acid as a model- active compound, by
using two types of polymers HPMC-METHO-
CEL (subtypes K4M, K15M and their mixture
in ratio 1:1) and PEO-POLYOX (subtypes
1105, 301 and their mixture in ratio 1:1), to
compare the obtained products on the basis of
physical features and drug release, and to con-
clude how different polymers affect the
physic-chemical properties of hydrophilic ex-
tended release matrix systems.
Materials and methods  
Materials
Ascorbic acid 97% DC was purchased from
ALAND NUTRECEUTICAL CO. LTD.
PEO-s (POLYOX 1105 and POLYOX 301)
and HPMC-s (METHOCEL K4M and
METHOCEL K15M) were obtained from
COLORCON®, UK. Cellulose Microcrys-
taline (MCC) (VIVAPUR 102) was purchased
from JRS PHARMA®, Germany, copovidone
(Kollidon VA64) from BASF®, Germany, an-
hydrous colloidal silica (AEROSIL) from
EVONIK®, Germany and magnesium stearate
from DR.PAUL LOHMANN®, Germany.
Methods
Powder mixture treatment and evaluation
All powder compounds (except magnesium
stearate) were accurately weighted, passed
through standard 1.1mm sieve and thoroughly
blended for 5 minutes in a PE bag. After being
mixed powders were evaluated for bulk den-
sity and tapped density (PhEur 7), compress-
ibility index (Carr’s index), Housner ratio and
angle of repose(standard funnel and petri dish
with radius of 4.75cm).
Tablet formulation and preparation
After mixing powder compounds, Mg stearate
was added to the powder mixture by passing
it through a standard sieve 1.1mm. The ob-
tained mixture was thoroughly mixed for pe-
riod of 1 minute in a PE bag. Matrix tablets
were prepared by direct compression using
FETTE 1200 rotary tablet press. Six batches
(P1, P2, P3, P4, P5, P6) of round white-yel-
lowish tablets with average mass of 650 mg
and diameter of 12 mm were obtained. Com-
plete composition (mg) of the tablets and the
role of each excipient is shown in table 1. 
P1 P2 P3 P4 P5 P6 function
Ascorbic acid 97% 361 361 361 361 361 361 Active compound
PEO-POLYOX 1105 195 / 97.5 / / / Hydrophilic polymer/resin
PEO-POLYOX 301 / 195 97.5 / / / Hydrophilic polymer/resin
HPMC-METHOCEL K4M / / / 195 / 97.5 Hydrophilic polymer
HPMC-METHOCEL K15M / / / / 195 97.5 Hydrophilic polymer
Cellulose microcrystaline 64.75 64.75 64.75 64.75 64.75 64.75 Insoluble filler
Copovidone 19.5 19.5 19.5 19.5 19.5 19.5 Binder 
Colloidal silica 3.25 3.25 3.25 3.25 3.25 3.25 Flow aid
Mg stearate 6.5 6.5 6.5 6.5 6.5 6.5 Lubricant 
Σ 650 650 650 650 650 650
Table 1- Composition of P1, P2, P3, P4, P5, P6 batch of tablets and compound function








PEO-POLYOX 1105 / / 8800-17600
PEO-POLYOX 301 1650-5500 / /
HPMC-METHOCEL K4M / 3000-5600 /
HPMC-METHOCEL K15M / 11250-21000 /
Table 2- Average viscosity of some hydrophilic polymers
Standard tablet evaluation
Tablets were examined on the basis of weight
uniformity (Mettler Toledo balance), friability
(Varian dual roche type drums), resistance to
crushing (Varian VK 200), estimation of drug
content (HPLC-Agilent technology 1200
RRLC, VWD detector). 
Dissolution test was made in accordance with
USP (paddle apparatus Varian VK7025),
75rpm speed, at temperature of 37°C, in phos-
phate buffer pH= 7.2 at time interval from
2,4,6,8, 10 and 12 hours . Amount of drug re-
lease was measured in the intervals of 2, 4, 6,
8, 10 and 12 hours and determined by HPLC
(Agilent technology 1200 RRLC, VWD detec-
tor). Our requirement was minimal 80 % drug
release in 12 hours period.
All tests were made in accordance with the
current edition of the European Pharmacopeia
(PhEur 7) and the United States Pharmacopeia
(USP 35)
Results and discussion  
Powder properties
Formulations containing HPMC had bulk den-
sity in range of 0.526 g/ml up to 0,540 g/ml
and tapped density from 0.702 g/l up to 0.741
g/ml, while formulations containing PEO
showed bulk density values from 0.541 g/ml
up to 0.588 g/ml and tapped density values
ranging from 0.678 g/ml up to 0.690 g/ml. By
comparing the results obtained for Compress-
ibility (Carr’s) index, Hausner ratio and angle
of repose  it could be concluded that powder
mixtures containing PEO (P4, P5, P6) show
better flow properties compared with powder
mixtures containing HPMC (P1, P2, P3). It is
considered that powders having Carr’s index
value up to 30%, Hausner ratio value less than
1.20 and angle of repose smaller than 35°
show good flow properties, and very often do
not require addition of flow aid compounds
[Zheng J, 2009]. However inclusion of col-
loidal anhydrous silica in all six formulations
provided obtaining powder mixtures with
good flowability, which was observed on siev-
ing and on tableting processes [Rowe et al,
2006].  The physical properties of the powder
blends are shown in Table 3. 
P1 P2 P3 P4 P5 P6
Bulk density (g/ml) 0,531 0,54 0,526 0,541 0,588 0,548
Tapped density (g/ml) 0,702 0,741 0,714 0,69 0,678 0,678
Carr's index (%) 24,36 27,12 26,33 21,59 13,27 19,17
Hausner ratio 1,32 1,37 1,36 1,27 1,15 1,24
Angle of repose 31,15 32,47 32,43 29,71 28,86 29,63
Table 3- Physical characteristics of powder mixtures
Tablet properties
By employing direct compression method on
a rotary tablet press, six batches of shine
white-yellowish tablets were produced. All six
batches complied the pharmacopoeial require-
ments (PhEur 7, USP 35) concerning average
mass, hardness, friability and drug content.
The tableting process was continuous and pro-
vided obtaining tablets whose mass didn’t tend
to vary more of 1%. Tablets containing PEO
showed slightly bigger hardness compared
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with tablets containing HPMC. It could be also
noted that tablets containing polymer with
higher molecular weight(HPMC K15M, PEO
301) show higher hardness values compared
to tablets composed of polymer with lower
molecular weight(HPMC K4M, PEO 1105).
The batches containing polymer blends tend
to settle their hardness values between those
shown by tablets composed of single poly-
mers. This could be due to phenomenon of ob-
taining median molecular weight when mixing
different polymers.  It is very important to
mention that all six batches of tablets had 0%
mass loss after friability testing, which shows
that they could withstand mechanical shock
and are suitable for coating without the possi-
bility to be physically damaged. The complete
results for standard tablet properties are shown
in table 4.
P1 P2 P3 P4 P5 P6
Average mass (mg) 649,6 652,5 653,09 647,95 648,41 650,3
Hardness (kP) 10,42 10,93 10,56 10,81 11,04 11,51
Friability (%) 0 0 0 0 0 0
Drug content (%) 99,41 100,4 101,65 98,27 99,85 101,67
Table 4- Standard tablet characteristics
Release profile results
According the results obtained from the in
vitro dissolution studies in pH=7.2, it was
noted that all formulations provided fast hy-
dration and swelling which resulted in fast for-
mation of an outer swelled gel layer and
uniform extended release of the active com-
pound over a period of 12 hours, by both dif-
fusion and erosion pathways. Tablets
containing HPMC showed lower levels of re-
leased active compound compared with tablets
containing PEO as a matrix forming polymer,
through the whole interval of 12 hours. PEO
matrices provided higher burst release in the
interval of 2 hours, and all of them at the end
of 12 hours released more than 80% of ascor-
bic acid. After 2 hour HPMC matrices released
15,21%-16.63% and PEO matrices released
23,17%-28,31%, after 4 hours HPMC matri-
ces released 25,37%-28.41% while PEO ma-
trices released 40,12%-49,90%, after 6 hours
HPMC matrices released 35,50%-36.67% and
PEO matrices released 52,30%-60,63%, after
8 hours HPMC matrices released 41,51%-
47.62%, while PEO matrices released
59,23%-71,14%, after 10 hours HPMC matri-
ces released 53,17%-56.87% and PEO matri-
ces released 70,12%-80,95%, after 12 hours
HPMC matrices released 62,85%-68.21%,
while PEO matrices released 81,57%-92,47%.
All these results could be due to the lover vis-
cosity of PEO1105 compared to HPMC K4M,
the lower viscosity of PEO 301 compared to
HPMC K15M, and the lower viscosity of PEO
mixture compared with HPMC mixture, which
lower viscosity of the polymer/s is connected
with higher degree of drug diffusion through
PEO matrices [Rowe et al, 2006]. Also the
higher percentage of released compound in the
case of PEO matrices could be connected with
the higher portion of eroded polymer which
was visually noted in the dissolution vessels
where tablets containing PEO were placed.
When comparing tablets consisting of HPMC
as matrix forming polymer, it was seen that
there were no significant differences in the re-
lease profiles of batch P1(containing HPMC
K4M) and batch P2(containing HPMC K15M)
up to 6 hours time period. In the intervals from
6 hours till 12 hours, tablets containing HPMC
K4M released slightly higher percent of ascor-
bic acid compared with matrices made of
HPMC K15M. This could be related with the
lower molecular weight and viscosity of
HPMC K4M compared with HPMC K15M
which leads to higher degree of water penetra-
tion into the matrix and higher degree of poly-
mer erosion in matrices made of HPMC K4M
[ref]. Tablets containing HPMC K4M and
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HPMC K15M mixture (P3) in a ratio 1:1
showed similar release profile as the matrices
containing single HPMC in the 6 hour interval,
while up to 12 hours the % of release vitamin
C was somewhere between the % of drug re-
leased from tablets containing single HPMC
K4M or HPMC K15M. PEO proved to be suit-
able polymer for developing extended release
matrix tablets [Prajapati et al, 2011]. From the
gained results it was shown that matrices con-
taining PEO 1105 (P4) showed significantly
higher release of active compound through the
total period of dissolution testing compared
with tablets containing PEO 301(P5). As men-
tioned before this is due to the lower molecular
weight and viscosity of PEO 1105 compared
with PE0 301, which leads to higher degree of
active substance release by both diffusion and
erosion mechanisms . Combining PEO 1105
and PEO 301 (ratio 1:1) in matrix tablets gave
very obvious preview of obtaining intermedi-
ate viscosity grade polymer mixture and inter-
mediate modified release profile of the active
compound. Through all 12 hours P6 batch
gave drug release results somewhere between
the dissolution results obtained for lower vis-
cosity grade PEO 1105 matrices and higher
viscosity PEO 301 matrices. From all the data
obtained it could be concluded that tablets
containing PEO 1105 as hydrophilic matrix
forming polymer were the most suitable op-
tion for developing 12 hours extended release
matrices of vitamin C treated as food supple-
ment, while matrices containing HPMC are
not suitable for this purpose, because of the
lower amount (max 68%) of drug released. All
results related to the dissolution studies and re-
lease profiles of the six batches hydrophilic
matrix tablets are shown in table 5 and picture
1.
P1 P2 P3 P4 P5 P6
After 2 hours (%) 16,63 15,21 16,57 28,31 23,17 26,91
After 4 hours (%) 25,37 27,11 28,41 49,9 40,12 42,72
After 6 hours (%) 36,57 35,5 34,85 60,63 52,3 53,59
After 8 hours (%) 47,62 41,51 45,36 71,14 59,23 59,64
After 10 hours (%) 56,87 53,17 55,12 80,95 70,12 71,56
After 12 hours (%) 68,21 62,85 67,71 92,47 81,57 82,85
Table 5- Dissolution profile of all six batches matrix tablets
Picture 1- Cumulative drug release of all six batches matrix tablets
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Conclusion 
Ascorbic acid (Vitamin C) is essential com-
pound for the human health and well-being.
The conventional supply of oral vitamin C by
standard 500 mg tablets, do not provide satis-
factory pharmacological activity because of
the high(almost complete) liberated amount of
active compound in maximum 30 minutes
(PhEur 7), which leads to lower absorption
level of this moiety. Also 500 mg supplies of
vitamin C are not considered as health supple-
ments but as medicines. The purpose of this
study was to develop extended release tablets
which will provide slower release of ascorbic
acid in smaller doses which could be easily ab-
sorbed by the GUT. We imagined and devel-
oped our product as direct compressible
matrix tablet made from 30% hydrophilic
polymer/s, which in contact with water or in-
testinal fluid will hydrate and swell, and will
provide formation of outer gelatinous layer.
This gelatinous layer acts as a barrier and
modulates the release of the active compound
from the matrices by two mechanisms: diffu-
sion and erosion. Six batches of matrix tablets
(P1-P6) were prepared and analysed for pow-
der properties, tablet properties and dissolu-
tion profile. Hydroxypropyl methylcellulose
(HPMC) with different molecular weight and
viscosity(HPMC K4M, HPMC K15M and
HPMC K4M + HPMC K15M mixture in 1:1
ratio) was used for production of first three
batches, while for the 4th ,5th and 6th batch a
hydrophilic polymer-resin polyethylene
oxide(PEO) was used. Two PEO’s- PEO 1105
and PEO 301 with different molecular weight
and viscosity, and their mixture in 1:1 ratio
were used for preparing the last three batches.
On the basis of powder properties, all six
batches showed good flowing properties and
didn’t tend to make any problems during the
tableting process. According the results ob-
tained for Carr’s index, Hausner ratio and
angle of repose batches containing PEO
showed better flowability compared with
batches containing HPMC. Concerning the re-
sults obtained for tablet properties (average
mass, hardness, friability, average content), all
six batches complied the pharmacopoeial de-
mands. By observing the results gained from
the dissolution studies for 12 hours in phos-
phate buffer pH=7.2, all six batches of matrix
tablets hydrated and swelled fast enough,
which provided rapid gel-layer formation and
uniform continuous delivery of ascorbic acid
through 12 hour period. Matrices made of
HPMC didn’t comply the requirement of min
80% drug liberation through total test period,
while all three batches made of PEO released
more than 80% of ascorbic acid. This could be
due to the lower viscosity of PEO 1105 com-
pared with HPMC K4M, PEO 301 compared
with HPMC K15, and PEO mixture compared
with HPMC mixture. The lower viscosity of
PEO’s leaded in formation of weaker gel layer
on the surface of the matrix tablets, which pro-
vide higher degree of drug release by both dif-
fusion and erosion. By comparing all three
batches of PEO matrices it was obviously
noted that tablets containing low viscosity
PEO 1105 released biggest amount of drug,
tablets containing high viscosity PEO 301 re-
leased lowest amount of drug, while matrices
containing 1:1 mixture of this two resins pro-
vided intermediate viscosity and drug release.
According the obtained results and our re-
quirements, batch P4 which contains PEO
1105 as matrix forming polymer was our
choice for further development of commer-
cially applicable product, because it gave uni-
form extended release of more than 90% of
ascorbic acid in period of 12 hours, demon-
strated good powder flowability and complied
the pharmacopeial requirement for tablet prop-
erties.
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RAZVOJ I EVALUACIJA FORMULACIJA MATRIKS TABLETA ASKORBINSKE
KISELINE SA PRODUŽENIM OSLOBADJANJEM  IZRADJENIM SA HIDROFIL-
NIM POLIMERIMA HIDROXIPROPILMETIL CELULOZOM I POLIETILENOK-
SIDOM
Aleksandar Aleksovski1*, Emilija Spaseska Aleksovska1, Midhat Jasić2
1 ZADA Pharmaceuticals, Bistarac Donji bb, Lukavac, BiH
2 Univerzitet u Tuzli, Farmaceutski fakultet, Tuzla, BiH
originalni naučni rad
Sažetak
Cilj: Cilj ovog rada je bio da se razvije formulacija tableta sa kontroliranim oslobadjanjem  koje
sadrže 350mg Askorbinske kiseline u hidrofilnom matriksu: Hidroksipropilmetil celuloze
(HPMC) različitih viskoznosti i u u hidrofilnom matriksu Polietilen oksida razlicitih viskoznosti
Materijale i metode: Bile su proizvedene šest serija matriks tablet. Korištena je 97% Askorbin-
ska kiselina za direktnu kompresiju kao aktivna supstanca. Kao hidrofilni polimeri koristili su
se HPMC K4M, HPMC K15M (Colorcon) I PEO 1105 i PEO 301 (Colorcon).Direktna kom-
presija je bila izabrana kao postupak izrade. U formulacijama koristila se Mikrokristalna celu-
loza kao punilo, kopovidon kao sredstvo za vezivanje, koloidalni silicijum dioksid za
poboljšanje protočnosti i magnezijum stearat kao lubrikans.
Prije tabletiranja mješavine aktivne i pomočnih supstanci bile su prosijane i odredjena im je
nasipna gustina, nasipni ugao, indeks kompresije i Hausner indeks. Dobijenim tabletama odred-
jivana je prosječna masa, otpornost na lom, habanje, sadržaj aktivne supstance i profil
rastvorljivosti u intervalu od 12 sati u fosfatnom puferu. Svi testovi su sprovedeni suglasno
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propisima i procedurama opisanim u PhEur7 i  USP35.
Rezultati: Svih šest formulacija su imale dobru protočnost, process tabletiranja je protekao bez
odstupanja. Dobijene tablet od svih šest fornmulacija odgovarale su farmakopejskim zahtjevima
u odnosu na prosječnu masu i variranje mase, otpornost na lom, habanje i sadržaj aktivne kom-
ponente. Ispitivanje profila olobadjanja aktivne supstance ukazalo je da svih šest formulacija
pokazuju  produženo oslobadjanje Askorbinske kiseline u interval od 12 sati; kod formulacija
izradjenih sa polietilen oksidima oslobadjanje je bilo veće od 80%. Iz dobijenih rezultata može
se konstatirati da polimeri sa nižom viskoznošću daju matrikse iz kojih se aktivna supstanca
brže oslobadja u usporedbi sa viskoznijim polimerima, a mješavine polimera PEO 1105/PEO
301 1:1 I HPMC K4M/HPMC K15M 1:1 daju matrikse sa intermedijernim oslobadjanjem što
je u skladu sa intermedijernom viskoznosti mješavine polimera.
Zaključak: Od dobijenih rezultata može se zaključiti da tablet koje sadrže PEO 1105 su naj-
pogodniji izbor za izradu tableta Askorbinske kiseline 350mg sa produženim oslobadjanjem u
interval od 12 sati.
Ključne riječi: Askorbinska kiselina, tablete sa produženim oslobađanjem, polimer,
hidroksipropil metilceluloza, polietilen oksid
